Short answer
If a family already has a known RET pathogenic variant linked to MEN2, the question is usually not whether to order a broad panel. It is whether a relative should get targeted testing for that exact family variant, so the team can sort inherited risk, childhood timing, thyroid planning, pheochromocytoma screening, and follow-up for siblings or children.
What family testing means
| Situation | Common next question | Why it matters |
|---|---|---|
| Known family RET pathogenic variant | Is the lab checking the exact same variant? | That is how you get a true family-variant answer. |
| Child or sibling at risk | Does age or MEN2 subtype change the plan? | Timing can be earlier in RET-related syndromes. |
| Negative result | Was it a true negative or an uninformative negative? | The wording changes what relatives still need to do. |
| VUS in the family | Can the family treat it like a positive result? | Usually not. A VUS is still uncertain until reclassified. |
Who usually gets tested first
- The affected relative with the clearest RET result is usually the anchor for cascade testing.
- First-degree relatives often come next because they have the highest chance of sharing the variant.
- Testing children can make sense when the family variant changes surveillance or preventive planning early in life.
- The exact report should state whether the test is germline family testing or something else, like tumor-only sequencing.
When children matter
RET-related MEN2 can be different from many adult-onset genetic conditions because some variants change childhood timing. That is why pediatric endocrinology or cancer genetics may be involved early, especially when the result could affect prophylactic thyroid planning or close surveillance before symptoms appear.
How to read results
| Result type | What it usually means | Next question |
|---|---|---|
| Positive for the known family RET variant | The relative likely inherited MEN2 risk for that variant. | What surveillance or preventive steps are next? |
| Negative for the known family variant | Usually a true negative for that family variant. | Does any other history still warrant follow-up? |
| VUS | Not a confirmed family risk result. | Will the lab reclassify it later? |
| Tumor-only RET finding | May reflect a somatic change rather than inherited risk. | Was germline confirmation recommended? |
Questions to ask
- What is the exact family RET variant, including codon and transcript notation?
- Is this a targeted family test or a broader hereditary cancer panel?
- Which relatives should be tested first, and who will help with cascade testing?
- Does the result affect calcitonin, thyroid ultrasound, adrenal screening, or calcium/parathyroid follow-up?
- How will the family know whether a negative is truly reassuring or just incomplete?
FAQ
What is MEN2 family variant testing?
It is targeted testing for the exact known RET variant already identified in the family, not broad tumor sequencing or a different hereditary panel.
Who should usually be tested first?
Usually the relative most likely to carry the known family RET variant is tested first, then cascade testing expands to other at-risk relatives.
Can children be tested?
Yes, when the family variant changes childhood MEN2 timing or preventive planning, testing can be appropriate much earlier than in many other genetic conditions.
Does a negative test rule out MEN2?
A true negative for the known family variant lowers inherited MEN2 risk for that variant, but the genetics team still checks whether any other testing or surveillance is needed.
What does a RET VUS mean in a family?
A variant of uncertain significance is not a confirmed family risk result, so it should not be treated like a pathogenic RET variant unless the lab later reclassifies it.
Why does sample type matter?
Blood or saliva usually means germline testing, while tumor-only testing can find somatic changes that do not answer the inherited family-risk question.